网站首页期刊介绍通知公告编 委 会投稿须知电子期刊广告合作联系我们
最新消息:
辛伐他汀联合雷公藤多苷对糖尿病肾病的疗效研究
作者:扈瑞春  徐国庆  任彦芳  张锐莹  景鑫  汤海波  李玉伶  陈秋月 
单位:廊坊市人民医院 肾内科, 河北 廊坊 065000
关键词:糖尿病肾病 辛伐他汀 雷公藤多苷 血脂 炎症因子 
分类号:R587.2
出版年·卷·期(页码):2018·46·第十期(1103-1107)
摘要:

目的:探讨辛伐他汀联合雷公藤多苷对糖尿病肾病的治疗效果。方法:选取我院收治的98例糖尿病肾病患者,按照随机数字表法均分为两组各49例:辛伐他汀组给予辛伐他汀治疗,联合治疗组在辛伐他汀治疗基础上给予雷公藤多苷,疗程3个月。观察两组总有效率、24 h尿蛋白定量(24 h UTP)、超敏C反应蛋白(hs-CRP)水平、肾功能、血脂水平以及不良反应。结果:治疗3个月后,联合治疗组总有效率为91.9%,明显高于辛伐他汀组的75.5%(P<0.05);两组24 h UTP和hs-CRP水平较治疗前明显降低(P<0.05),治疗1、2、3个月后联合治疗组比辛伐他汀组降低更明显(P<0.05);两组患者血肌酐(SCr)、尿素氮(BUN)、总胆固醇(TC)、三酰甘油(TG)和低密度脂蛋白胆固醇(LDL-C)水平等较治疗前明显降低(P<0.05),联合治疗组比辛伐他汀组降低更显著(P<0.05);两组不良反应发生率差异无统计学意义(P>0.05)。结论:辛伐他汀联合雷公藤多苷对糖尿病肾病的疗效显著,可有效改善肾功能,降低血脂和hs-CRP水平,安全可靠,值得推广应用。

Objective:To explore the therapeutic effect of simvastatin combined with Tripterygium on patients with diabetic nephropathy. Methods:Ninety-eight patients with diabetic nephropathy treated in our hospital were divided into simvastatin group (n=49) and combination group (n=49) by random number table method. The simvastatin group received simvastatin while the combination group was treated with Tripterygium glycosides in addition to simvastatin. After 3-month treatment, the total effective rate, 24 h urinary total protein (24 h UTP), hypersensitive C-reactive protein (hs-CRP), renal function, blood lipid and adverse reactions were observed. Results:After treatment for 3 months, the total effective rate (91.9%) in the combination group was much higher than that 75.5% of the simvastatin group (P<0.05). The levels of 24 h UTP and hs-CRP in the two groups were much lower than those before the treatment (P<0.05), while the levels in combination group were much lower than those in simvastatin group after treatment for 1 month, 2 months and 3 months (P<0.05). The levels of SCr, BUN, TC, TG and LDL-C in the two groups were significantly decreased compared with those before the treatment (P<0.05). Compared with simvastatin group, the levels in combination group were decreased more significantly. And there was no statistically significant difference in adverse reactions between the two groups (P>0.05). Conclusion:The treatment of simvastatin combined with Tripterygium glycosides is effective for patients with diabetic nephropathy, which can improve the renal function and reduce the levels of serum lipid and hs-CRP. It is safe, reliable and worthy of clinical application.

参考文献:

[1] 赵鹏鸣,王俭勤,梁耀军.内皮细胞损伤在糖尿病肾病发病机制中的作用[J].中国糖尿病杂志,2016,24(2):169-172.
[2] 陆世龙,王龙龙,黄国东.中医药治疗早期糖尿病肾病的研究进展[J].辽宁中医杂志,2016(5):1101-1103.
[3] 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2013年版)[J].中华内分泌代谢杂志,2014,30(10):447-498.
[4] 胡筱娟,秦艳,刘恬园,等.糖尿病肾病中医证型与肾络瘀阻相关性临床探讨[J].辽宁中医杂志,2016(1):91-92.
[5] 刘阳桦.血清CysC、Hcy、BUN、SCr水平检测对早期糖尿病肾病诊断的价值[J].贵州医药,2016,40(8):863-865.
[6] 石格,毛志敏,万毅刚,等.糖尿病肾病足细胞损伤的病理机制及中药的干预作用[J].中国中药杂志,2016,41(13):2416-2421.
[7] 吴海樱,史菀萍,尤尚前.雷公藤多苷为主三联药物方案治疗糖尿病肾病Ⅲ期临床研究[J].中国医师进修杂志,2016,39(5):468-470.
[8] 周瑞琴,李小巧,杨艳琴.雷公藤多苷对早期糖尿病肾病患者的血管内皮功能及T淋巴细胞亚群的影响[J].世界中医药,2017,12(8):1840-1843.
[9] 徐光标,陈德君,陈伟珍.雷公藤多苷片对糖尿病肾病患者临床疗效及炎症因子水平影响研究[J].中华中医药学刊,2017(8):2206-2208.
[10] 董元正,杨焕荣.雷公藤多苷对早期糖尿病肾病微炎症状态的干预研究[J].中国医药导报,2016,13(30):16-19.
[11] MAGEE C,GRIEVE D J,WATSON C J,et al.Diabetic nephropathy:a tangled web to unweave[J].Cardiovasc Drugs Ther,2017,31(5):579-592.
[12] 贺海东,徐旭东.糖尿病肾病患者胃肠激素测定及其临床意义[J].东南大学学报(医学版),2013,32(1):64-66.
[13] 聂丽华,曾昭良,潘东.白细胞介素因子与不同分型糖尿病肾病之间的关系探讨[J].贵州医药,2017,41(8):830-832.
[14] 李一北,盛梅笑,许陵冬,等.雷公藤多苷治疗糖尿病肾病疗效观察[J].山东中医杂志,2017(5):374-378.

服务与反馈:
文章下载】【发表评论】【查看评论】【加入收藏
提示:您还未登录,请登录!点此登录
您是第 235942 位访问者


 ©《现代医学》编辑部
联系电话:025-83272479;83272481
电子邮件: xdyx@pub.seu.edu.cn

苏ICP备09058541